⌘K
t
RTW Biotech Opportunities Ltd announced that on 19 November 2025, it bought back 100,000 of its Ordinary Shares at a price of $1.8621 per share. These repurchased shares will be held in treasury, resulting in 18,843,791 Ordinary Shares held in treasury and 327,123,649 total voting rights. This buyback was conducted under a shareholder authority granted in June 2025, which permits repurchases of up to 14.99% of its Ordinary Shares.
| Date | 20 Nov 2025 |
| Time | 07:00:04 |
| Category | Capital structure |
| ID | 2452I |
LEI: 549300Q7EXQQH6KF7Z84
20 November 2025
RTW Biotech Opportunities Ltd
(the "Company")
Transaction in Own Shares
The Company announces that on 19 November 2025 it bought back 100,000 of its Ordinary Shares at a price $1.8621 per Ordinary Share.
The repurchased Ordinary Shares will be held by the Company in treasury. Following the purchase and settlement of these Ordinary Shares, the Company's issued Ordinary Share capital is 345,967,440 of which 18,843,791 Ordinary Shares will be held in treasury, which attract no voting rights. Therefore, the total voting rights in the Company will be 327,123,649.
The Company has bought back these Ordinary Shares under the authority granted by shareholders at its Annual General Meeting in June 2025, which permits the Company to repurchase a maximum of 14.99% of its Ordinary Shares. The actual number of Ordinary Shares repurchased by the Company will depend on market conditions. This authority lasts until the next shareholder authority granted (expected to be at the Annual General Meeting in 2026), or until expressly revoked by shareholders.
The above figure of 327,123,649 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
No maximum consideration payable has been determined by the Company, but the Company is unable to pay a price for any Ordinary Shares pursuant to the buyback which would equate to a premium to the net asset value. It is the Company's current intention to hold any Ordinary Shares bought back in treasury.
The Company has instructed Deutsche Numis as its broker in respect of its buyback transactions. This arrangement is in accordance with the FCA Listing Rules and the Company's general authority to repurchase shares.
Enquiries:
|
RTW Investments, LP - Investment Manager Oliver Kenyon (Business & Corporate Development) Woody Stileman (Business Development) Krisha McCune (Investor Relations)
|
+44 (0)20 7959 6361 biotechopportunities@rtwfunds.com |
|
Deutsche Numis - Joint Corporate Broker Freddie Barnfield Nathan Brown Euan Brown
|
+44 (0)20 7260 1000 |
About RTW Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.